EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In Vitro Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes

Islam Alfreahat, Hamdi Nsairat iD, Ibrahim Deeb Aldeeb, Ali Al-Samydai, Walhan Alshaer

Technology in Cancer Research & Treatment · 2025

DOI: 10.1177/15330338241312561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2025. Verfasst von Islam Alfreahat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Doxorubicin, Liposomes, Clarithromycin, Antibiotics, Antineoplastic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Doxorubicin (DOX) is a potent chemotherapeutic agent for breast cancer, but its effectiveness is often diminished by resistance mechanisms, particularly through p-glycoprotein (P-gp) mediated drug efflux. Clarithromycin (CAM), a macrolide antibiotic, inhibits multiple metabolic pathways including CYP3A and P-gp, potentially countering DOX resistance.

Objective

This study aimed to evaluate the potentiation of DOX and its effectiveness against the MCF-7 breast cancer cell line by encapsulating both DOX and CAM in PEGylated liposomes.

Methods

PEGylated liposomes containing DOX and CAM were prepared using the thin film hydration method. The physicochemical properties of the liposomes, including average particle size, polydispersity index (PDI), and zeta potential, were characterized. Encapsulation efficiencies for CAM and DOX were assessed, and stability of the liposomes was evaluated over 9 days at room temperature. Cell viability was measured using an IC 50 assay, and P-gp expression levels were determined by ELISA.

Results

The CAM/DOX-PEGylated liposomes exhibited optimal average particle size (238 ± 26.7 nm), PDI (0.29 ± 0.107), and zeta potential (−20.9 ± 2.17 mV). These liposomes maintained good stability regarding size and charge over 9 days. Encapsulation efficiencies were 81.05% for CAM and 78.13% for DOX. The IC50 value for CAM/DOX-PEGylated liposomes was 0.13 µM, representing a significant reduction compared to the physical mixture of CAM and DOX (0.25 µM) and free DOX (0.21 µM) against MCF-7 cells. ELISA analysis showed a reduction in P-gp expression of approximately 5% with CAM/DOX-PEGylated liposomes compared to 1.61% with free DOX.

Conclusion

The results indicate that CAM encapsulated in PEGylated liposomes enhances the effectiveness of DOX against breast cancer cells, likely through the inhibition of p-glycoprotein. This approach may offer a promising strategy to overcome DOX resistance and improve chemotherapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinLiposomesClarithromycinAntibiotics, AntineoplasticBreast NeoplasmsHumansPolyethylene GlycolsMCF-7 CellsCell SurvivalDrug SynergismFemaleParticle SizeDrug Resistance, NeoplasmATP Binding Cassette Transporter, Subfamily B, Member 1

Stichwörter der Autor:innen

PEGylated liposomesclarithromycincytotoxicitydoxorubicinp-gp inhibitor

Substanzen

DoxorubicinLiposomesClarithromycinPolyethylene GlycolsAntibiotics, AntineoplasticATP Binding Cassette Transporter, Subfamily B, Member 1

Autor:innen und Institutionen

  • Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.
  • Cell Therapy Center, The University of Jordan, Amman, Jordan.

ORCID-Profile: Hamdi Nsairat

Zitieren

APA

Alfreahat, I., Nsairat, H., Aldeeb, I. D., Al-Samydai, A., & Alshaer, W. (2025). In Vitro Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241312561

Vancouver

Alfreahat I, Nsairat H, Aldeeb ID, Al-Samydai A, Alshaer W. In Vitro Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes. Technology in Cancer Research & Treatment. 2025. doi:10.1177/15330338241312561

BibTeX
@article{Alfreahat2025,
  author = {Alfreahat, Islam and Nsairat, Hamdi and Aldeeb, Ibrahim Deeb and Al-Samydai, Ali and Alshaer, Walhan},
  title = {In Vitro Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes},
  journal = {Technology in Cancer Research & Treatment},
  year = {2025},
  doi = {10.1177/15330338241312561}
}
Kostenlos starten →